{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069826","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.077993+00:00","generated_at":"2026-05-21T17:47:06.010486+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Candel Therapeutics Q1 net income $7.4M; cash runway into Q1 2027; CAN-2409 BLA on track","bullets":["Net income of $7.4M in Q1 2025 vs net loss of $8.2M in Q1 2024, driven by warrant liability fair value change.","Cash and equivalents $92.2M as of March 31, 2025; expected to fund operations into Q1 2027.","CAN-2409 phase 3 prostate cancer meets primary endpoint; BLA submission expected Q4 2026.","CAN-2409 in borderline resectable PDAC: mOS 31.4 months vs 12.5 months control in phase 2a.","CAN-2409 in NSCLC (ICI-progressive): mOS 21.5 months vs 9.8–11.8 months standard of care."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069826","json":"https://secwatch.observer/filing/0000950170-25-069826.json","markdown":"https://secwatch.observer/filing/0000950170-25-069826.md","text":"https://secwatch.observer/filing/0000950170-25-069826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025069826/0000950170-25-069826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025069826/cadl-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:47:06.010486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}